Michelle Vanase‐Frawley

Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy

Christine P. Diggle, Stacey J. Sukoff Rizzo, Michael Popiolek et al. · The American Journal of Human Genetics · 2016 · 81 citations · Full text

Life Sciences, Molecular Genetics, Neuroscience +13

Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo

Robin J. Kleiman, Douglas S. Chapin, Curt Christoffersen et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 80 citations

Life Sciences, Neuroscience, Pharmacology +17

Design and Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders

Patrick R. Verhoest, Kari R. Fonseca, Xinjun Hou et al. · Journal of Medicinal Chemistry · 2012 · 72 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy

Patrick R. Verhoest, Caroline Proulx-LaFrance, Michael L. Corman et al. · Journal of Medicinal Chemistry · 2009 · 65 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Pharmacological Characterization of 2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a High-Affinity Antagonist Selective for κ-Opioid Receptors

S. Grimwood, Yang Lü, Anne W. Schmidt et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 59 citations

Medicine, Medicinal Chemistry, Pharmacology +14